Clinical and biological forms of secondary hyperparathyroidism in dialysis patients;Les formes cliniques et biologiques de l'hyperparathyroïdie secondaire en dialyse

Nephrologie et Therapeutique

Volumn 8, Issue 1, 2012, Pages 35-40

  Jean, Guillaume ^a   Souberbielle, Jean Claude ^b   Lorriaux, Christie ^a   Mayor, Brice ^a   Hurot, Jean Marc ^a   Deleaval, Patrick ^a   Chazot, Charles ^a  

^a Centre de Rein Artificiel de Tassin   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Bone markers; Calcimimetics; Haemodialysis; Hyperparathyroidism; Parathyroid hormone; Parathyroidectomy; Vitamin D

Indexed keywords

CALCITRIOL DERIVATIVE; CINACALCET; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; VITAMIN D;

ARTICLE; DISEASE COURSE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PATHOPHYSIOLOGY; SECONDARY HYPERPARATHYROIDISM; VITAMIN SUPPLEMENTATION;

ADULT; AGED; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 84857231583     PISSN: 17697255     EISSN: 18729177     Source Type: Journal    
DOI: 10.1016/j.nephro.2011.05.002     Document Type: Article

References (20)

1. C.M. Kdigo Work Group Kdigo clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) Kidney Int 76 2009 S1 130
2. G.A. Block, and F.K. Port Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management Am J Kidney Dis 35 2000 1226 1237 (Pubitemid 30354431)
3. C. Kumata, M. Mizobuchi, H. Ogata, F. Koiwa, A. Nakazawa, and F. Kondo Involvement of alpha-klotho and fibroblast growth factor receptor in the development of secondary hyperparathyroidism Am J Nephrol 31 2010 230 238
4. M. Rodriguez, E. Nemeth, and D. Martin The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism Am J Physiol Renal Physiol 288 2005 F253 264
5. Y. Tominaga, H. Johansson, and H. Takagi Secondary hyperparathyroidism: pathophysiology, histopathology, and medical and surgical management Surg Today 27 1997 787 792 (Pubitemid 27382698)
6. J.C. Souberbielle, A. Boutten, M.C. Carlier, D. Chevenne, G. Coumaros, and E. Lawson-Body Inter-method variability in PTH measurement: implication for the care of ckd patients Kidney Int 70 2006 345 350 (Pubitemid 44086584)
7. P. Urena, and M.C. De Vernejoul Circulating biochemical markers of bone remodeling in uremic patients Kidney Int 55 1999 2141 2156 (Pubitemid 29256470)
8. P.U. Torres Calcimimetics: physiology, results of preclinical and clinical studies, and perspectives Néphrologie & Thérapeutique 7 2011 99 104
9. G. Jean, T. Vanel, J.C. Terrat, J.M. Hurot, C. Lorriaux, and B. Mayor Treatment of secondary hyperparathyroidism resistant to conventional therapy and tertiary hyperparathyroidism with cinacalcet: an efficiency strategy Néphrologie & Thérapeutique 6 2010 105 110
10. P. Messa, F. Macario, M. Yaqoob, K. Bouman, J. Braun, and B. von Albertini The optima study: assessing a new cinacalcet (sensipar/mimpara) treatment algorithm for secondary hyperparathyroidism Clin J Am Soc Nephrol 3 2008 36 45
11. W.L. St Peter, J. Liu, E. Weinhandl, and Q. Fan A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the dialysis clinical outcomes revisited (DCOR) randomized trial using claims data Am J Kidney Dis 51 2008 445 454 (Pubitemid 351273476)
12. P. Raggi, G.M. Chertow, P.U. Torres, B. Csiky, A. Naso, and K. Nossuli The advance study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis Nephrol Dial Transplant 26 4 2011 1327 1339
13. G.M. Chertow, L.B. Pupim, G.A. Block, R. Correa-Rotter, T.B. Drueke, and J. Floege Evaluation of cinacalcet therapy to lower cardiovascular events (Evolve): rationale and design overview Clin J Am Soc Nephrol 2 2007 898 905
14. G. Eknoyan, A. Levin, and N.W. Levin Bone metabolism and disease in chronic kidney disease Am J Kidney Dis 42 2003 1 201
15. S. Okuno, M. Inaba, K. Kitatani, E. Ishimura, T. Yamakawa, and Y. Nishizawa Serum levels of C-terminal telopeptide of type 1 collagen: a useful new marker of cortical bone loss in hemodialysis patients Osteoporos Int 16 2005 501 509
16. P. Urena, M. Hruby, A. Ferreira, K.S. Ang, and M.C. de Vernejoul Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients J Am Soc Nephrol 7 1996 506 512 (Pubitemid 26128321)
17. F.C. Barreto, D.V. Barreto, R.M. Moyses, K.R. Neves, M.E. Canziani, and S.A. Draibe K/DOQI-recommended intact pth levels do not prevent low-turnover bone disease in hemodialysis patients Kidney Int 73 2008 771 777 (Pubitemid 351323258)
18. G. Jean, C. Chazot, and B. Charra Twelve months cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism: effect on bone markers Clin Nephrol 68 2007 63 64 (Pubitemid 47045498)
19. E. Slatopolsky, A. Brown, and A. Dusso Role of phosphorus in the pathogenesis of secondary hyperparathyroidism Am J Kidney Dis 37 2001 S54 57
20. E. Slatopolsky, A. Brown, and A. Dusso Pathogenesis of secondary hyperparathyroidism Kidney Int Suppl 73 1999 S14 19